RESEARCH PAPER
Patterns of cyclin A and B1 immunostaining in papillary thyroid carcinoma
 
More details
Hide details
1
Department of Endocrinology and Metabolic Diseases, Polish Mother`s Memorial Hospital – Research Institute, Lodz, Poland
2
Department of General, Oncological and Endocrine Surgery, Polish Mother`s Memorial Hospital – Research Institute, Lodz, Poland
CORRESPONDING AUTHOR
Andrzej Lewiński   

Department of Endocrinology and Metabolic Diseases, Polish Mother`s Memorial Hospital – Research Institute, Lodz, Poland
 
Ann Agric Environ Med. 2015;22(4):741–746
KEYWORDS
ABSTRACT
Introduction and objectives:
Cyclin A, encoded by CCNA (cyclin A) gene with locus in chromosome 4q27, and cyclin B1, encoded by CCNB1 (cyclin B1) gene with locus in chromosome 5q12, are proteins that play a key role in the passage through the restriction point in G2 phase of the cell cycle. The aim of the study was to analyse immunohistochemically the expression of cyclins A and B1 in different variants of papillary thyroid carcinoma (PTC).

Material and Methods:
The immunostaining patterns of the proteins in question in the tissue of 40 resected PTC (20 cases of classic variant of PTC, 9 cases of PTC follicular variant and 11 cases of other non-classic variants of PTC) were investigated.

Results:
On analyzing cyclin A and B1 expression, positive staining in 90% cases of PTC were observed. The study revealed a significant difference in expression of cyclins A and B1 between classic and non-classic variants of PTC. The expression of both examined cyclins was weaker in the classic variant of PTC. In the group of follicular variant of PTC, the expression of cyclins was of medium intensity and in the group of other non-classic variants of PTC, the expression was clearly higher.

Conclusions:
The results of the presented study suggest that cyclins A and B1 expression may have a characteristic pattern of immunostaining for particular variants of PTC. If the obtained results are confirmed in a larger group of patients, the diagnostic panel constructed of the antibodies against these proteins may increase the diagnostic accuracy in PTC cases.

 
REFERENCES (25)
1.
Brzeziańska E, Karbownik M, Migdalska-Sęk M, Pastuszak-Lewandowska D, Włoch J, Lewiński A. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Mutat Res. 2006; 599(1–2): 26–35.
 
2.
Cyniak-Magierska A, Brzeziańska E, Januszkiewicz-Caulier J, Jarząb B, Lewiński A. Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS. Exp Clin Endocrinol Diabetes. 2007; 115(9): 594–599.
 
3.
Brzeziańska E, Pastuszak-Lewandoska D, Wojciechowska K, Migdalska-Sęk M, Cyniak-Magierska A, Nawrot E, et al. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in Polish population. Neuro Endocrinol Lett. 2007; 28(4): 351–359.
 
4.
Pines J, Hunter T. Cyclins A and B1 in the human cell cycle. Ciba Found Symp. 1992; 170: 187–204.
 
5.
Chibazakura T, Kamachi K, Ohara M, Tane S, Yoshikawa H, Roberts JM. Cyclin A promotes S-phase entry via interaction with the replication licensing factor Mcm7. Mol Cell Biol. 2011; 31(2): 248–255.
 
6.
Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjallskog ML, Blomqvist C. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology. 2007; 51(4): 491–498.
 
7.
Murakami H, Furihata M, Ohtsuki Y, Ogoshi S. Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma. Virchows Arch. 1999; 434(2): 153–158.
 
8.
Jin YH, Park CK. Expression of cyclin B1 and cdc2 in nodal non-Hodgkin’s lymphoma and its prognostic implications. J Korean Med Sci. 2002; 17 (3): 322–327.
 
9.
DeLeilis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. WHO classification of tumours. Lyon: IARC Press; 2004.
 
10.
Thyroid in: American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7 th ed. New York, NY: Springer 2010, pp 87–96.
 
11.
Brzeziński J, Migodziński A, Gosek A, Tazbir J, Dedecjus M. Cyclin E expression in papillary thyroid carcinoma – relations to staging. Int J Cancer. 2004; 109(1): 102–105.
 
12.
Brzeziańska E, Cyniak-Magierska A, Sporny S, Pastuszak-Lewandoska D, Lewiński A. Assessment of cyklin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions. Neuro Endocrinol Lett. 2007; 28(4):341–350.
 
13.
Lewiński A, Brzeziańska E, Czarnecka K, Latek J, Koptas W, Cyniak-Magierska A. Increased expression of PIN1 gene in papillary thyroid carcinoma. Thyroid Res. 2011; 4(1): 4.
 
14.
Brzeziński J, Migodziński A, Toczek A, Tazbir J, Dedecjus M. Patterns of cyclin E, retinoblastoma protein, and p21 Cip1/WAF1 immunostaining in the oncogenesis of papillary thyroid carcinoma. Clin Cancer Res. 2005; 11(3): 1037–1043.
 
15.
Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J, et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer. 2002; 86(3):402–8.
 
16.
Baldini E, Camerini A, Sgambato A, Prochilo T, Capodanno A, Pasqualetti, et al. Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients. Anticancer Res. 2006; 26(6B):4415–21.
 
17.
Suzuki T, Urano T, Miki Y, Moriya T, Akahira J, Ishida T, et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 2007; 98(5):644–51.
 
18.
Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, et al. Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid. 2007; 17(7): 639–646.
 
19.
Hooft L, van der Veldt AA, Hoekstra OS, Boers M, Molthoff CF, van Diest PJ. Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodules. Clin Endocrinol (Oxf). 2008; 68(2): 252–257.
 
20.
Ito Y, Yoshida H, Matsuzuka F, Matsuura N, Nakamura Y, Nakamine H, et al. Cdc2 expression in primary thyroid lymphoma: its relationship with biological aggressiveness and G2 cyclins. Pathol Res Pract. 2003; 199 (8): 533–538.
 
21.
Ito Y, Yoshida H, Nakano K, Takamura Y, Kobayashi K, Yokozawa T, et al. Expression of G2-M modulators in thyroid neoplasms: correlation of cyclin A, B1 and cdc2 with differentiation. Pathol Res Pract. 2002; 198(6): 397–402.
 
22.
Dinets A, Hulchiy M, Sofiadis A, Ghaderi M, Höög A, Larsson C, et al. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma. Eur J Endocrinol. 2012; 166(6): 1049–1060.
 
23.
Nar A, Ozen O, Tutuncu NB, Demirhan B. Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma. Med Oncol. 2012; 29(1): 294–300.
 
24.
Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms. World J Surg. 2006; 30(5): 767–774.
 
25.
Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res. 2005;11(4):1521–6.
 
eISSN:1898-2263
ISSN:1232-1966